IMNN•benzinga•
IMUNON Announces FDA Alignment On CMC Strategy For IMNN-001 In Advanced Ovarian Cancer, Phase 3 Trial Set To Begin Q1 2025 With cGMP Manufacturing Process And Potency Assay Approved For Clinical And Commercial Use
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 19, 2024 by benzinga